Skip to main content

Table 2 ObsQoR-11 of parturients

From: The efficacy and safety of intrathecal dexmedetomidine for parturients undergoing cesarean section: a double-blind randomized controlled trial

 

Group B (n = 100)

Group FB (n = 100)

Group DB (n = 100)

P-Value

Moderate pain

3.6 ± 1.1

5.6 ± 0.9*

7.3 ± 1.2*#

< 0.001

Severe pain

4.4 ± 1.2

5.0 ± 2.1*

7.5 ± 1.6*#

< 0.001

Nausea or vomiting

5.2 ± 1.0

6.0 ± 0.9*

7.3 ± 1.2*#

< 0.001

Feeling dizzy

6.3 ± 1.2

5.0 ± 0.8*

6.3 ± 1.1#

< 0.001

Shivering

3.7 ± 0.8

5.3 ± 0.7*

7.2 ± 1.0*#

< 0.001

Have been comfortable

6.4 ± 1.0

6.4 ± 0.6

7.4 ± 1.8*#

< 0.001

Able to mobilize independently

6.0 ± 1.9

6.9 ± 1.5*

6.9 ± 1.1*

< 0.001

Can hold baby without assistance

6.9 ± 0.8

8.2 ± 0.7*

8.1 ± 0.8*

< 0.001

Can feed/nurse baby without assistance

6.6 ± 0.7

7.0 ± 1.0*

7.1 ± 0.7*

< 0.001

Can look after personal hygiene/toilet

5.6 ± 0.9

6.3 ± 0.6*

6.5 ± 0.9*

< 0.001

Feeling in control

7.0 ± 0.8

7.3 ± 1.0*

8.0 ± 0.8*#

< 0.001

Total

61.7 ± 3.3

61.5 ± 3.6

71.6 ± 3.1*#

< 0.001

  1. Notes: Data are presented as mean ± SD; Group B = bupivacaine group; Group FB = bupivacaine and fentanyl group; Group DB = bupivacaine and dexmedetomidine group; ObsQoR-11 = obstetric quality of recovery-11 score, 0–10 in each term, where 0 = strongly agree and 10 = strongly disagree
  2. * P < 0.017 Group DB or Group FB vs Group B; #P < 0.017 Group DB vs Group FB